Trophos neurology news
Trophos concluded the three-year MitoTarget project, an EU-funded consortium of 17 academic and research partners to research the use of mitochondrial-targeted molecules to treat neurodegenerative diseases. In 2008, the European Commission awarded a three-year grant of about €6 million ($8.7 million) to the consortium's MitoTarget project to fund a Phase III trial of Trophos' olesoxime to treat amyotrophic lateral sclerosis (ALS) and other preclinical target research. Trophos, which led the consortium, said that the project confirmed that mitochondrial dysfunction "plays an important role in neuron death, and therefore the progression of neurodegenerative diseases," and contributed towards broader research to discover which dysfunction is the leading cause of neurodegenerative diseases. ...